Compare Analog Devices, Inc. (ADI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Novavax Inc — how do they compare? Analog Devices, Inc. trades at $393.99 (market cap $187.67B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Analog Devices, Inc. is far larger — about 143.3× Novavax Inc's market cap, and Analog Devices, Inc. pays a 1.14% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ADI | NVAX | |
|---|---|---|
Market Cap | $187.67B | $1.31B |
Sector | Technology | Health |
52-Week High | $445.48 | $11.19 |
52-Week Low | $225.20 | $6.22 |
Enterprise Value | $192.92B | $889.30M |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $383.93, down 1.54% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 26.01% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights institutional buying and a spin-off of ADI Global Distribution, completed August 4, 2026, as per a Business Wire report.
The outlook is positive, supported by a strong analyst consensus with a $472.29 price target and no sell ratings. Key opportunities include consistent earnings outperformance and exposure to semiconductor sector growth. Risks involve high valuation multiples and potential market volatility impacting the stock's premium pricing.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
